The Innovation Scorecard reports on the use of medicines and medical technologies in the NHS in England, which have been positively appraised by the National Institute for Health and Care Excellence (NICE). It can be used by local NHS organisations to monitor progress in implementing NICE Technology Appraisal (TA) recommendations.

The Innovation Scorecard measures use of individual medicines and medicine groupings in the NHS in England, 

The Innovation Scorecard aims to improve transparency within the NHS of what treatments recommended by NICE are available at a local level within Trusts and CCGs as well as national and NHS England Region levels. The Innovation Scorecard has been published with the intention of assisting the NHS in the identification of variation, which, through discussion, can be explained, challenged or acted upon. It is not intended to be used for performance management.

When interpreting the data there are a number of considerations:

• medicines can be used to treat multiple conditions
• a condition can be treated with various medicines
• one medicine may displace another, for example, for treatment of hepatitis C teleprevir and boceprevir is an older class of medicine and shows a large decrease in contrast to ombitasvir-paritaprevir-ritonavir that is a newer class of medicine and has increased in use
• for a typical uptake curve the rate of increase is rapid in the early years but eases off over time